Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice

Cancer Science

Volumn 100, Issue 11, 2009, Pages 2226-2233

  Jiang, Xian ^a   Li, Hali ^a   Qiao, Haiquan ^a   Jiang, Hongchi ^a   Xu, Ruian ^b   Sun, Xueying ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HUAQIAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CASPASE 3; CYCLINE; KALLISTATIN; KI 67 ANTIGEN; MELOXICAM; PROTEIN BAX; PROTEIN BCL 2; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2 INHIBITORS; GENE THERAPY; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; SERPINS; THIAZINES; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71049128260     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01306.x     Document Type: Article

References (53)

1. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122:1609-19.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999, 353:1253-7.
3. Kinoshita S, Hirai R, Yamano T. Angiogenesis inhibitor TNP-470 can suppress hepatocellular carcinoma growth without retarding liver regeneration after partial hepatectomy. Surg Today 2004, 34:40-6.
4. Ishikawa H, Nakao K, Matsumoto K. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology 2003, 37:696-704.
5. Graepler F, Verbeek B, Graeter T. Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 2004, 41:879-86.
6. Ma L, Luo L, Qiao H. Vasostatin synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. J Hepatol 2006, 46:98-106.
7. Chao J, Chai KX, Chen LM. Tissue kallikrein-binding protein is a serpin, I: purification,characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 1990, 265:16394-401.
8. Miao RQ, Agata J, Chao L. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002, 100:3245-52.
9. Chao J, Miao RQ, Chen V, Chen LM, Chao L. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem 2001, 382:15-21.
10. Zhu B, Lu L, Cai W. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 2007, 6:3297-306.
11. Lu L, Yang Z, Zhu B. Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Lett 2007, 257:97-106.
12. Diao Y, Ma J, Xiao WD. Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin. World J Gastroenterol 2007, 13:4615-9.
13. Tse LY, Sun X, Jiang H. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. J Gene Med 2008, 10:508-17.
14. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997, 57:1276-80.
15. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998, 58:4997-5001.
16. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998, 90:455-60.
17. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schrör K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999, 59:198-204.
18. Tucker ON, Dannenberg AJ, Yang EK. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999, 59:987-90.
19. Shiota G, Okubo M, Noumi T. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999, 46:407-12.
20. Bae SH, Jung ES, Park YM. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001, 7:1410-8.
21. Kern MA, Schöneweiss MM, Sahi D. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 2004, 25:1193-9.
22. Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer 2007, 110:791-800.
23. Hattori K, Iida K, Joraku A, Tsukamoto S, Akaza H, Oyasu R. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int 2006, 97:640-3.
24. Tsuchida A, Itoi T, Kasuya K. Inhibitory effect of meloxicam, a cyclooxygenase-2 inhibitor, on N-nitrosobis (2-oxopropyl) amine induced biliary carcinogenesis in Syrian hamsters. Carcinogenesis 2005, 26:1922-8.
25. Teh SH, Hill AK, Foley DA, McDermott EW, O'Higgins NJ, Young LS. COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells. J Cell Biochem 2004, 91:796-807.
26. Tsubouchi Y, Mukai S, Kawahito Y. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 2000, 20:2867-72.
27. Goldman AP, Williams CS, Sheng H. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998, 19:2195-9.
28. Kern MA, Schubert D, Sahi D. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002, 36:885-94.
29. Kern MA, Schirmacher P, Breinig M. Significance of cyclooxygenase-2 as a chemotherapeutic target in hepatocellular carcinoma [Article in German]. Verh Dtsch Ges Pathol 2007, 91:257-68.
30. Dohmen K, Okabe H, Ishibashi H. Regression of hepatocellular carcinoma due to cyclooxygenase (COX)-2 inhibitor. Am J Gastroenterol 2006, 101:2437-8.
31. Li J, Chen X, Dong X, Xu Z, Jiang H, Sun X. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells. J Gastroenterol Hepatol 2006, 21:1814-20.
32. Liu F, Wang P, Jiang X. Antisense hypoxia-inducible factor 1 α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinomas. Cancer Sci 2008, 99:2055-61.
33. Chen H, Sun B, Pan S, Jiang H, Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 2009, 20:131-40.
34. Miao RQ, Chen V, Chao L. Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol 2003, 284:C1604-13.
35. Zhou GX, Chao L, Chao J. Kallistatin: a novel human tissue kallikrein inhibitor: purification, characterization, and reactive center sequence. J Biol Chem 1992, 267:25873-80.
36. Dawson DW, Volpert OV, Gillis P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-8.
37. O'Reilly MS, Piri e-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999, 285:1926-8.
38. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000, 6:196-9.
39. Schoeffner DJ, Matheny SL, Akahane T. VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab Invest 2005, 85:608-23.
40. Barr MP, Byrne AM, Duffy AM. A peptide corresponding to the neuropilin-1-binding site on VEGF (165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer 2005, 92:328-33.
41. Chao J, Tillman DM, Wang MY. Identification of a new tissue-kallikrein-binding protein. Biochem J 1986, 239:325-31.
42. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004, 4:876-90.
43. Hengartner MO. The biochemistry of apoptosis. Nature 2000, 407:770-6.
44. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006, 43:1-67.
45. Yamanaka Y, Shiraki K, Inoue T. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 2006, 18:41-7.
46. Jones MK, Wang H, Peskar BM. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999, 5:1418-23.
47. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit alphaVbeta3 integrin-mediated and Cdc42/Rac-dependent endothelial cell spreading, migration and angiogenesis. Nat Med 2001, 7:1041-7.
48. Ishizaki T, Katsumata K, Tsuchida A. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med 2006, 17:357-62.
49. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996, 93:14765-70.
50. Griscelli F, Li H, Bennaceur-Griscelli A. Angiostatingene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998, 95:6367-72.
51. Nooijen PT, Manusama ER, Eggermont AM. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 1996, 74:1908-15.
52. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-9.
53. Abdollahi A, Hlatky L, Huber PE. Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 2005, 8:59-74.